BIXTOTCPharmaceutical PreparationsFiscal year ends December 31
BIOXYTRAN, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.02−0.00 (-3.95%)
Close on Oct 19, 2026
- Market cap
- $2.56M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Bioxytran has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Bioxytran filed with the SEC
Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID,
Other events · EX-99.1 to Form 8-K
Inc. Completes $1.2 Million Private Placement
Unregistered share sale · Other events · EX-99.1 to Form 8-K
Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
Other events · EX-99.1 to Form 8-K
Inc. Announces Commercial Distribution Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
REPORTS POSITIVE PHASE 2 RESULTS
Other events · EX-99.1 to Form 8-K
Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
Material agreement · Other events · EX-99.1 to Form 8-K
Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
Other events · EX-99.1 to Form 8-K
Bioxytran Measures the Presence of Carbon Monoxide
Other events · EX-99.1 to Form 8-K
Launches Joint Venture with the Heme Foundation for Development of a Universal Oxygen Carrier
Material agreement · Other events · EX-99.1 to Form 8-K
BXT-25 Drug Acts as a Universal Oxygen Carrier Like Hyperbaric Oxygenation for Stroke & Alzheimer’s Patients
Other events · EX-99.1 to Form 8-K
Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Other events · EX-99.1 to Form 8-K
Expands Institutional Investor Base with an additional $500,000 Equity Investment
Material agreement · Other events · EX-99.1 to Form 8-K